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Abstract
Background: This study aimed to screen multiple genes biomarkers based on gene expression data for predicting
the survival of ovarian cancer patients.
Methods: Two microarray data of ovarian cancer samples were collected from The Cancer Genome Atlas (TCGA)
database. The data in the training set were used to construct Reactome functional interactions network, which then
underwent Markov clustering, supervised principal components, Cox proportional hazard model to screen
significantly prognosis related modules. The distinguishing ability of each module for survival was further evaluated
by the testing set. Gene Ontology (GO) functional and pathway annotations were performed to identify the roles of
genes in each module for ovarian cancer.
Results: The network based approach identified two 7-gene functional interaction modules (31: DCLRE1A, EXO1,
KIAA0101, KIN, PCNA, POLD3, POLD2; 35: DKK3, FABP3, IRF1, AIM2, GBP1, GBP2, IRF2) that are associated with prognosis
of ovarian cancer patients. These network modules are related to DNA repair, replication, immune and cytokine
mediated signaling pathways.
Conclusions: The two 7-gene expression signatures may be accurate predictors of clinical outcome in patients with
ovarian cancer and has the potential to develop new therapeutic strategies for ovarian cancer patients.
Keywords: Ovarian cancer, Reactome functional interactions, Markov clustering, Supervised principal components,
Prognosis
Background
Ovarian cancer is the most common lethal gynecologic
malignancy in women worldwide, with an estimated
22,280 newly diagnosed cases and approximately 14,240
deaths in 2016 in the United States [1]. Due to the lack
of specific symptoms and effective screening tests, ap-
proximately 70 % of ovarian cancer patients have been
in advanced-stage (stage III or IV) when they are firstly
diagnosed, leading to the 5-year survival rate of less than
30 % [2]. By contrast, patients who are diagnosed with
early-stage (stage I or II) have a 5-year survival rate of
up to 70–90 % [2]. These data indicate the importance
to identify the sensitive biomarkers to early distinguish
the patients with different prognosis, aiming to deter-
mine optimal treatment strategies.
In the past years, remarkable achievements have been
obtained in the investigation of prognostic markers for
ovarian cancer. For instance, a 10-gene signature
(AEBP1, COL11A1, COL5A1, COL6A2, LOX, POSTN,
SNAI2, THBS2, TIMP3, and VCAN) has been validated
to be associated with poor overall survival in patients
with high-grade serous ovarian cancer [3]. The presence
of a BRCA1 or BRCA2 mutation is associated with a bet-
ter prognosis in patients with invasive ovarian cancer
[4]. A recent study has found that suppression of
ABHD2 in OVCA420 cells increased phosphorylated
p38 and ERK, platinum resistance, and side population
cells, promoting a malignant phenotype and poor prog-
nosis in serous ovarian cancer [5]. Furthermore, CD73
enhances ovarian tumor cell growth and expression of
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antiapoptotic BCL-2 family members, indicating a role
of CD73 as a prognostic marker of patient survival in
high-grade serous ovarian cancer [6]. Although the
aforementioned genes have been shown to be correlated
with the prognosis in ovarian cancer, their prognostic
accuracy may be limited because the development of
disease usually involves several genes and the interaction
between them to form a complex pathway. Therefore, it
is necessary to identify gene networks and pathways
including multiple genes and their interactions, which
can be achieved by Reactome functional interaction (FI)
network construction as described previously [7, 8].
In the present study, we aimed to construct the Reac-
tome FIs network to analyze the gene signatures that
was significantly related to ovarian cancer patient sur-
vival based on gene expression profiling data extracted
from The Cancer Genome Atlas (TCGA) database.
Methods
As the paper did not involve any human or animal, the
ethical approval was not required.
Gene expression data
Two gene expression datasets with their corresponding
clinical data (including survival status and time) for
ovarian cancer samples were downloaded from TCGA
database (https://tcga-data.nci.nih.gov/tcga). Data of one
gene expression dataset were produced from the BI-HT-
HG-U133A platform, in which 536 samples were in-
cluded and 12042 genes were expressed in each sample
(defined as BI). The other gene expression profiling from
559 ovarian cancer patients was produced from the
UNC-AgilentG4502A-07-3 microarray platform, in
which 17814 genes were included (defined as U3). These
two datasets were randomly divided into training (BI) or
testing sets (U3).
Construction of Reactome FI network
The annotated FIs were extracted from five pathway da-
tabases, including Reactome [9], kyoto encyclopedia of
genes and genomes (KEGG) [10], protein annotation
through evolutionary relationship (Panther) [11], The
Cancer Cell Map (http://cancer.cellmap.org/), and NCI
Pathway Interaction Database (NCI-PID) [12]. The pro-
tein FIs were predicted by physical protein-protein inter-
actions (PPIs) in human organisms (catalogued in the
Biological General Repository for Interaction Datasets
(BioGrid) [13], the Human Protein Reference Database
(HPRD) [14] and IntACT [15]), model organisms (from
IntAct [15] based on Ensembl Compara [16]), and pro-
tein domain–domain interactions (from PFam [17]). The
naive Bayes classifier, a simple machine learning method
[18], was used to score the probability that a protein
pair-wise relationship reflects a functional pathway
event, during which the annotated FIs were selected as
positive training sets, whereas the predicted FIs were
defined as negative training sets. Subsequently, the gene
expression data of BI from the TCGA were mapped into
the constructed Reactome FIs via co-expression relation-
ships (calculated by Pearson correlation) to distribute
the weight of each edge.
Markov clustering (MCL)
The gene/protein correlations in the Reactome FI network
were input into the Reactome FI Cytoscape plugin (MCL)
[7] to generate a sub-network for a list of selected network
modules based on module size (≥7) and average correl-
ation (Pearson correlation coefficient ≥0.25). To control
the size of network modules generated from the MCL
clustering, the inflation coefficient was set as 5.0.
Analysis of prognosis-related modules
The prognosis-related modules were further predicted
based on the supervised principal components (superpc)
[19] using the Superpc V1.05 software package under
the programming environment R (http://statweb.stanfor-
d.edu/~tibs/superpc/). A module-based gene expression
matrix was generated by using mean expression level of
genes in each module across 536 ovarian cancer sam-
ples, and then underwent the superpc analysis. A 10-fold
cross-validation curve was performed for estimating the
best threshold. In addition, Cox proportional hazard
(PH) model was also performed to correlate each mod-
ule with survival data (p < 0.05), followed by Kaplan-
Meier analysis to demonstrate the distinguishing ability
of each module for survival.
Gene Ontology (GO) functional and pathway annotations
The genes in prognosis-related modules were subjected
to the GO and pathway enrichment analyses to identify
their roles in ovarian cancer. GO and pathway functional
annotations were conducted for the survival-associated
genes using the Reactome FI plug-in of Cytoscape [20].
False discovery rate (FDR) < 0.05 was used for a thresh-
old to assess the statistical significance.
Results
Data information
Two datasets [BI-HT-HG-U133A (BI), and UNC-
AgilentG4502A-07-3(U2)] were obtained from TCGA.
The BI dataset contained 536 samples, and expression
data of 12042 genes were included in each sample. The
U2 dataset contained 559 samples, and expression data
of 17814 genes were included in each sample. In this
study, BI was used as the training dataset, and U2 was
used as the test dataset (Fig. 1).
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Analysis of the FI network and modules
Based on the BI dataset, a weighted FI network includ-
ing 710 proteins and 9516 interactions were constructed.
Subsequently, using MCL network clustering, a total of
41 modules were obtained, and the number of genes in
each module ranged from 7 to 118. Furthermore, using
the Superpc package with a threshold value of 0.73, 14
prognosis-related modules were identified from the 41
modules (Table 1). Afterwards, 6 significant modules
(modules 6, 8, 20, 26, 31 and 35) with the p-value < 0.05
were identified from the 14 modules based on the Cox
PH analysis (Table 2). These 6 modules were validated
by the U2 dataset, and two modules (modules 31 and 35)
were also significant in the U2 dataset. Thus, modules 31
and 35 were further analyzed.
Analysis of modules 31 and 35
A set of 7 genes (DCLRE1A, EXO1, KIAA0101, KIN,
PCNA, POLD3, POLD2) were included in the module 31
(Fig. 2a), and 7 genes (DKK3, FABP3, IRF1, AIM2, GBP1,
GBP2, IRF2) were included in the module 35 (Fig. 2b).
Kaplan-Meier plot demonstrated that the gene expression
in these two modules can significantly distinguish the
patients with longer and shorter survivals (Fig. 3).
To further investigate the biological functions of the
genes in modules 31 and 35, GO and pathway annota-
tions were performed. The genes in module 31 were
mainly related to the functions of DNA repair, DNA
replication and cell cycle (Fig. 4). The genes in module
35 were significantly associated with functions about
immune and cytokine or interferon mediated signaling
pathways (Fig. 5).
Fig. 1 The flow chart of the whole analysis in this study
Table 1 Superpc analysis for prognosis related modules
according to 10-fold cross-validation method















Table 2 Cox proportional hazard analysis for prognosis related
modules using the training (BI) and test datasets (U3)
Module Size BI U3
Likelihood ratio p-value Likelihood ratio p-value
26 9 9.41 0.002 0.32 0.574
20 10 6.91 0.009 3.58 0.058
31 7 7.43 0.006 4.45 0.035
35 7 6.19 0.013 6.25 0.012
6 22 5.96 0.015 2.57 0.109
8 21 6.22 0.013 0.67 0.414
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Discussion
In this study, a total of 41 modules were obtained from
the FI network based on the expression data in the BI
dataset. Using MCL network clustering, superpc model-
ing and Cox PH analysis, two modules, modules 31 and
35, were identified to be significantly associated with
prognosis of ovarian cancer patients. Seven genes were
included in the two modules (31: DCLRE1A, EXO1,
KIAA0101, KIN, PCNA, POLD3, POLD2; 35: DKK3,
FABP3, IRF1, AIM2, GBP1, GBP2, IRF2). Furthermore,
the genes in module 31 were related to DNA repair or
replication, whereas the genes in module 35 were associ-
ated with immune and cytokine interferon mediated
signaling pathways.
DCLRE1, also known as SNM1A, belongs to a member
of a small gene family that is characterized by a metallo-
β-lactamase fold and an appended β-CASP domain that
together are proposed to function as a DNA endonucle-
ase to participate in DNA inter-strand cross-link repair
[21]. DNA cross-link repair is beneficial to maintain
genomic stability and enables cells to survive DNA dam-
age, contributing to less risk of tumorigenesis [22]. How-
ever, recent studies indicate that the high efficiency of
DNA cross-link repair may also promote the excessive
proliferation of cells, driving tumor initiation and pro-
gression [23–25]. Thus, down-regulation of DNA repair
genes may be a promising target for anticancer therapy
[26], which has been demonstrated by the study of Wu
et al. [27]. Wu et al. have found that DCLRE1A is signifi-
cantly decreased by bufalin, which promotes lung cancer
apoptosis [27]. In addition, inhibition of DNA cross-link
repair was also proved to reverse treatment resistance
and improve the therapeutic efficacy [28].
EXO1 encodes exonuclease and plays important roles in
mismatch repair by resecting the damaged strand. Similar
to DCLRE1A, Exo1 is also shown to be higher expressed
in tumor tissues than that in the normal tissues [29, 30]. A
previous study has demonstrated that FOXM1 facilitates
DNA repair through regulating direct transcriptional tar-
get EXO1 to protect ovarian cancer cells from cisplatin-
mediated apoptosis, and attenuating EXO1 expression by
small interfering RNA augments the cisplatin sensitivity of
ovarian cancer cells [31]. POLD2 or POLD3 are both the
subunits of DNA polymerase delta that possesses both
polymerase and 3′ to 5′ exonuclease activity and plays a
critical role in DNA replication and repair [32]. POLD2
was found to be increased in average 2.5- to almost 20-
fold in moderately and poorly differentiated serous carcin-
omas of epithelial ovarian cancer, eventually leading to
poor prognosis [33].
Furthermore, proliferating cell nuclear antigen (PCNA)
is a ring-shaped homo-triomeric protein that functions as
a necessary clamping platform to recruit numerous en-
zymes involved in DNA replication and repair, such as
DNA polymerases, endonuclease, and DNA ligase, ultim-
ately responsible for cell proliferation [34]. Therefore,
Fig. 2 Kaplan-Meier survival plot for the module 31 (a) and 35 (b). All samples were divided into two groups based on the median value of gene
expression in modules. The green curve is for samples having lower expression, while the red curve for samples having higher expression
Fig. 3 Genes and interaction relationship in the module 31 (a) and
35 (b). The arrow indicates the co-expression relationship and known
pathway regulatory relationship; the dotted line indicates the newly
predicted interaction; the full line indicates the common complex
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PCNA is widely considered as a biomarker for cancer pro-
gression and prognosis. A recent study has found that
PCNA was expressed in 52.2 % of gastric cancer patients,
and positive expression of PCNA was significantly associ-
ated with poor 3-year disease-free survival (p = 0.035) [35].
KIAA0101 is a 15-kDa protein that has a conserved motif
to bind to PCNA via a yeast two-hybrid system and thus
involved in the regulation of DNA repair and cell prolifer-
ation [36]. Similar to PCNA, overexpression of KIAA0101
can promote growth and invasion of cancer cells [37] and
predict poor prognosis in cancer patients [38, 39]. Collect-
ively, these genes in the module 31 may play critical roles
in the prognosis of ovarian cancer via regulation of DNA
repair and cell proliferation.
In the module 35, 7 genes were included. Interferon
regulatory factor 1 (IRF1) is a member of the interferon
regulatory transcription factor (IRF) family, which can
cause the inhibition of cell proliferation and stimulation
of apoptosis [40]. IRF2 is a functional antagonist of IRF1
and may act as an oncogene, promoting the formation
and progression of cancer [41]. A previous study has
demonstrated that increased level of IRF1 is associated
with both increased progression-free and overall survival
of patients with ovarian carcinoma, and IRF1 is an inde-
pendent predictor of platinum resistance and survival in
high-grade serous ovarian carcinoma [42]. Furthermore,
IRF1 directly mediates the interferon-γ (IFN-γ)-induced
apoptosis via the activation of caspase-1 gene expression
in IFN-γ-sensitive ovarian cancer cells [43]. However, in
a recent study of ovarian cancer, IRF-1 was identified to
be up-regulated in ovarian cancer samples compared
with healthy ovarian tissue although strong expression
Fig. 4 GO functional and KEGG pathway enrichment analyses of the genes in the module 31. MF, CC and BP are the three categories of the GO
functional enrichment analysis. GO Gene Ontology, KEGG Kyoto Encyclopedia Of Genes And Genomes, BP biological process, CC cellular
component, MF molecular function
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of IRF-1 predicted improved disease-free survival and
overall survival [44]. This finding may be attributed to a
compensation or adaptation mechanism. Further study
indicated the IRF1 seemed to play a key role in the tran-
scriptional activation of interferon-inducible guanylate
binding proteins (GBP1 and GBP2) [45], which subse-
quently induces T-lymphocyte immune response against
the cancer cell spreading and proliferation [46]. There-
fore, GBP1 and GBP2 may be also tumor suppressor
genes and associated with better prognosis [47].
AIM2 is another human IFN-inducible protein, which
forms the AIM2 inflammasome with an adaptor protein
ASC upon sensing foreign cytoplasmic double-stranded
DNA [48]. The activated AIM2 inflammasome in macro-
phages promotes the proteolytic cleavage and secretion
of pro-inflammatory cytokines (IL-1β and IL-18)
through the activation of caspase-1, leading to cell sen-
escence, apoptosis and preventing cancer progression
[49]. Thereby, AMI2 may be also correlated with excel-
lent prognosis [50, 51].
Conclusion
Based on gene expression profiling data, two 7-gene
functional interaction modules were identified to be
likely associated with prognosis of ovarian cancer pa-
tients. These network modules were related to DNA re-
pair, replication, immune and cytokine mediated
signaling pathways. However, further experimental stud-





Availability of data and material
The raw data were collected and analyzed by the Authors, and are not ready
to share their data because the data have not been published.
Authors’ contributions
XW,SSW and LZ carried out all the operations,designed and applied the
technique. And they had also critically reviewed the final draft of the
manuscript. LY and LMZ collected the data,wrote the manuscript,conceived
of the study,participated in its design and coordination and found and
organized the literature. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Department of Gynaecology and Obstetrics, The 306 Hospital of PLA, Beijing
100037, China. 2Outpatient Pharmacy, Outpatient Department, NO.16
Chengzhuang Fengtai Distinct, Beijing 100071, China.
Fig. 5 GO functional and KEGG pathway enrichment analyses of the genes in the module 35. MF, CC and BP are the three categories of the GO
functional enrichment analysis. GO Gene Ontology, KEGG Kyoto Encyclopedia Of Genes And Genomes, BP biological process, CC cellular
component, MF molecular function
Wang et al. Journal of Ovarian Research  (2016) 9:73 Page 6 of 8
Received: 28 August 2016 Accepted: 25 October 2016
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin.
2016;66(1):10–29.
2. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al.
Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol.
2012;120(3):612–8.
3. Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, et al. A collagen-
remodeling gene signature regulated by TGFβ signaling is associated with
metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014;
20(3):711–23.
4. Mclaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, et al. Long-term
ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl
Cancer Inst. 2013;105(2):141–8.
5. Yamanoi K, Matsumura N, Murphy SK, Baba T, Abiko K, Hamanishi J, et al.
Suppression of ABHD2, identified through a functional genomics screen,
causes anoikis resistance, chemoresistance and poor prognosis in ovarian
cancer. Oncotarget. 2016
6. Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, et al.
CD73 is associated with poor prognosis in high-grade serous ovarian
cancer. Cancer Res. 2015;75(21):4494–503.
7. Wu G, Stein L. A network module-based method for identifying cancer
prognostic signatures. Genome Biol. 2012;13(12):R112.
8. Wu G, Feng X, Stein L. A human functional protein interaction network and
its application to cancer data analysis. Genome Biol. 2010;11(5):R53.
9. Vastrik I, D'Eustachio P, Schmidt E, Joshi-Tope G, Gopinath G, Croft D, et al.
Reactome: a knowledge base of biologic pathways and processes. Genome
Biol. 2007;8(3):R39.
10. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG
resource for deciphering the genome. Nucleic Acids Res. 2004;32 suppl
1:D277–80.
11. Mi H, Dong Q, Muruganujan A, Gaudet P, Lewis S, Thomas PD. PANTHER
version 7: improved phylogenetic trees, orthologs and collaboration with
the Gene Ontology Consortium. Nucleic Acids Res. 2010;38
suppl 1:D204–10.
12. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, et al. PID: the
pathway interaction database. Nucleic Acids Res. 2009;37 suppl 1:D674–9.
13. Chatr-Aryamontri A, Breitkreutz B-J, Heinicke S, Boucher L, Winter A, Stark C,
et al. The BioGRID interaction database: 2013 update. Nucleic Acids Res.
2013;41(D1):D816–23.
14. Prasad TK, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S,
et al. Human protein reference database—2009 update. Nucleic Acids Res.
2009;37 suppl 1:D767–72.
15. Kerrien S, Alam-Faruque Y, Aranda B, Bancarz I, Bridge A, Derow C, et al.
IntAct—open source resource for molecular interaction data. Nucleic Acids
Res. 2007;35 suppl 1:D561–5.
16. Flicek P, Aken BL, Ballester B, Beal K, Bragin E, Brent S, et al. Ensembl’s 10th
year. Nucleic Acids Res. 2010;38 suppl 1:D557–62.
17. Finn RD, Mistry J, Schuster-Böckler B, Griffiths-Jones S, Hollich V, Lassmann T,
et al. Pfam: clans, web tools and services. Nucleic Acids Res. 2006;34
suppl 1:D247–51.
18. Murakami Y, Mizuguchi K. Applying the Naïve Bayes classifier with kernel
density estimation to the prediction of protein–protein interaction sites.
Bioinformatics. 2010;26(15):1841–8.
19. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival
from gene expression data. PLoS Biol. 2004;2(4):E108.
20. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T. Cytoscape 2.8: new
features for data integration and network visualization. Bioinformatics.
2011;27(3):431–2.
21. Yan Y, Akhter S, Zhang X, Legerski R. The multifunctional SNM1 gene family:
not just nucleases. Future Oncol. 2010;6(6):1015–29.
22. Ahkter S, Richie CT, Zhang N, Behringer RR, Zhu C, Legerski RJ. Snm1-
deficient mice exhibit accelerated tumorigenesis and susceptibility to
infection. Mol Cell Biol. 2005;25(22):10071–8.
23. Herrera M, Dominguez G, Garcia JM, Peña C, Jimenez C, Silva J, et al.
Differences in repair of DNA cross-links between lymphocytes and epithelial
tumor cells from colon cancer patients measured in vitro with the comet
assay. Clin Cancer Res. 2009;15(17):5466–72.
24. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A,
Dessen P, et al. High expression of DNA repair pathways is associated with
metastasis in melanoma patients. Oncogene. 2008;27(5):565–73.
25. van Gent DC, Kanaar R. Exploiting DNA repair defects for novel cancer
therapies. Mol Biol Cell. 2016;27(14):2145–8.
26. Abbotts R, Thompson N, Madhusudan S. DNA repair in cancer: emerging
targets for personalized therapy. Cancer Manag Res. 2014;6:77.
27. Wu S-H, Hsiao Y-T, Chen J-C, Lin J-H, Hsu S-C, Hsia T-C, et al. Bufalin alters
gene expressions associated DNA damage, cell cycle, and apoptosis in
human lung cancer NCI-H460 cells in vitro. Molecules. 2014;19(5):6047–57.
28. Ledermann JA, Gabra H, Jayson GC, Spanswick VJ, Rustin GJ, Jitlal M, et al.
Inhibition of carboplatin-induced DNA interstrand cross-link repair by
gemcitabine in patients receiving these drugs for platinum-resistant ovarian
cancer. Clin Cancer Res. 2010;16(19):4899–905.
29. Ioana M, Angelescu C, Burada F, Mixich F, Riza A, Dumitrescu T, et al. MMR
gene expression pattern in sporadic colorectal cancer. J Gastrointestin Liver
Dis. 2010;19(2):155–9.
30. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM,
Kemmner W. Identification of early molecular markers for breast cancer. Mol
Cancer. 2011;10(1):15.
31. Zhou J, Wang Y, Yin X, He Y, Chen L, Wang W, et al. FOXM1 modulates
cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS One.
2014;9(5):e96989–9.
32. Tian X, Swenberg J, Nakamura J. POLD3 is required for DNA damage
response to endogenous and exogenous DNA damage in human cells.
Cancer Res. 2013;73(8 Supplement):1281–1.
33. Elgaaen BV, Haug KBF, Wang J, Olstad OK, Fortunati D, Onsrud M, et al.
POLD2 and KSP37 (FGFBP2) correlate strongly with histology, stage and
outcome in ovarian carcinomas. 2010.
34. Essers J, Theil AF, Baldeyron C, van Cappellen WA, Houtsmuller AB, Kanaar R,
et al. Nuclear dynamics of PCNA in DNA replication and repair. Mol Cell Biol.
2005;25(21):9350–9.
35. Li N, Deng W, Ma J, Wei B, Guo K, Shen W, et al. Prognostic evaluation of
Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer.
Med Oncol. 2015;32(1):1–9.
36. Yu P, Huang B, Shen M, Lau C, Chan E, Michel J, et al. p15^ P^ A^ F, a
novel PCNA associated factor with increased expression in tumor tissues.
Oncogene. 2001;20(4):484–9.
37. Jain M, Zhang L, Patterson EE, Kebebew E. KIAA0101 is overexpressed, and
promotes growth and invasion in adrenal cancer. PLoS One.
2011;6(11):e26866.
38. Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M. Overexpression of
KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung
Cancer. 2012;75(1):110–8.
39. Su X, Zhang T, Cheng P, Zhu Y, Li H, Li D, et al. KIAA0101 mRNA
overexpression in peripheral blood mononuclear cells acts as predictive
marker for hepatic cancer. Tumor Biol. 2014;35(3):2681–6.
40. Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, et al.
Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in
breast cancer associated with caspase activation and induction of apoptosis.
Carcinogenesis. 2005;26(9):1527–35.
41. Cui L, Deng Y, Rong Y, Lou W, Mao Z, Feng Y, et al. IRF-2 is over-expressed
in pancreatic cancer and promotes the growth of pancreatic cancer cells.
Tumor Biol. 2012;33(1):247–55.
42. Cohen S, Mosig R, Moshier E, Pereira E, Rahaman J, Prasad-Hayes M, et al.
Interferon regulatory factor 1 is an independent predictor of platinum
resistance and survival in high-grade serous ovarian carcinoma. Gynecol
Oncol. 2014;134(3):591–8.
43. Kim EJ, Lee JM, Namkoong SE, Um SJ, Park JS. Interferon regulatory factor-1
mediates interferon-γ-induced apoptosis in ovarian carcinoma cells. J Cell
Biochem. 2002;85(2):369–80.
44. Zeimet AG, Reimer D, Wolf D, Fiegl H, Concin N, Wiedemair A, et al.
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance
in predicting patient outcome in ovarian cancer. Int J Cancer.
2009;124(10):2353–60.
45. Ramsauer K, Farlik M, Zupkovitz G, Seiser C, Kröger A, Hauser H, et al.
Distinct modes of action applied by transcription factors STAT1 and IRF1 to
initiate transcription of the IFN-γ-inducible gbp2 gene. Proc Natl Acad Sci.
2007;104(8):2849–54.
46. Godoy P, Cadenas C, Hellwig B, Marchan R, Stewart J, Reif R, et al.
Interferon-inducible guanylate binding protein (GBP2) is associated with
Wang et al. Journal of Ovarian Research  (2016) 9:73 Page 7 of 8
better prognosis in breast cancer and indicates an efficient T cell response.
Breast Cancer. 2014;21(4):491–9.
47. Britzen-Laurent N, Lipnik K, Ocker M, Naschberger E, Schellerer VS, Croner
RS, et al. GBP-1 acts as a tumor suppressor in colorectal cancer cells.
Carcinogenesis. 2013;34(1):153–62.
48. Fernandesalnemri T, Yu JW, Datta P, Wu J, Alnemri ES. AIM2 activates the
inflammasome and cell death in response to cytoplasmic DNA. Nature.
2009;458(7237):509–13.
49. Ponomareva L, Liu H, Duan X, Dickerson E, Shen H, Panchanathan R, et al. AIM2,
an IFN-inducible cytosolic DNA sensor, in the development of benign prostate
hyperplasia and prostate cancer. Mol Cancer Res. 2013;11(10):1193–202.
50. Dihlmann S, Tao S, Echterdiek F, Herpel E, Jansen L, Chang-Claude J, et al.
Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely
associated with poor survival in colorectal cancer patients. Int J Cancer.
2014;135(10):2387–96.
51. Liu R, Truax AD, Chen L, Hu P, Li Z, Chen J, et al. Expression profile of innate
immune receptors, NLRs and AIM2, in human colorectal cancer: correlation
with cancer stages and inflammasome components. Oncotarget. 2015;6(32):
33456–69.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wang et al. Journal of Ovarian Research  (2016) 9:73 Page 8 of 8
